Xencor, Inc.

Good day and thank you for standing by. Welcome to the third quarter 2021 CENCOR conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker today, Charles Lyles, Head of Corporate Communications and Investor Relations. Please go ahead.

Thank you, and good afternoon. Earlier today, we issued a press release which outlines the topics we plan to discuss today. The press release is available at www.zencore.com. With me on the call today are Basil Dahyat, President and Chief Executive Officer, Alan Yang, Chief Medical Officer, John Desjarlais, Chief Scientific Officer, and John Cush, Chief Financial Officer. After the remarks, we'll open up the call for your questions. Before we begin, I would like to remind you that during the course of this conference call, Zencore Management may make forward-looking statements, including statements regarding the company's future financial and operating results, future market conditions, the plans and objectives of management, future operations, the company's partnering efforts, capital requirements, future product offerings, and research and development programs. These forward-looking statements are not historical facts, but rather are based on our current expectations and beliefs and are based on information currently available to us. The outcome of the events described in these forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including but not limited to those factors contained in the risk factor section of our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q. With that, let me pass the call over to Basil. Thanks, Charles, and good afternoon, everyone.

We've used our array of modular protein engineering tools to create our internal development portfolio in oncology and autoimmune disease that currently includes six bispecific antibodies, either in phase one or phase two studies, and two cytokines in phase one. Our portfolio approach allows us to take multiple simultaneous shots on goal in the clinic, and the proof of concept data we generate guides which programs we advance, which we terminate, or which we partner. Today we've announced data from the first of our cytokine programs, XMAP306, a reduced-potency, long-acting IL-15 FC fusion protein in co-development with Genentech, which Alan will touch on momentarily. But first, a quick update on our collaborations. Last month, we entered a global collaboration and license agreement with Janssen to advance Plimodimab, our CD20 by CD3 bispecific antibody, and to create novel CD28 bispecific antibodies against malignant B cells to combine with Plimodimab and potentially other CD3 bispecifics in lymphoma. The HSR waiting period expired last week, and the agreement is closed. We're delighted to expand our ongoing CD28 work with the Janssen team and to plan Pomodamab development together. We believe collaborating with Janssen is the best way to broaden and accelerate our efforts in lymphoma and to maximize the opportunity for Pomodamab to bring benefit to patients in a very promising and crowded field. Just a few other updates across our partners' programs, which incorporate our plug-and-play XMAP FC domains. Now, in August, tafacitimab, which was created and initially developed by us, was granted conditional marketing authorization by the European Commission in combination with lenalidomide for the treatment of adult patients with relapsed or refractory to huge large B-cell lymphoma who were not eligible for autologous stem cell transplantation. In the EU, tafacitimab is marketed by Insight as Minjuvi, while in the U.S. it's co-marketed by Insight and Morphosis as Monjuvi. We're also pleased that our partners, VR and GSK, continue to receive emergency or temporary authorizations for citrovimab, their investigational SARS-CoV-2 antibody that incorporates our Xtend technology in countries across the globe for the treatment of mild to moderate COVID-19 in high-risk adults and pediatric patients. So with these two products, Monjuvi and citrovimab, along with Altamiris from the Alexion unit of AstraZeneca, our partnerships have resulted now in three marketed XMAP medicines, which are available to treat patients with a range of serious illnesses. Now, with that, we'll turn to Alan Yang, our chief medical officer, who will review our recent clinical highlights and upcoming plans.